Skip to main content
SpringerLink
Log in

Clinical pharmacology of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193)

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

A pharmacokinetic study of tiazofurin was carried out in 13 patients treated in a phase I clinical trial of the drug and in 7 patients undergoing surgical resection of brain tumor (in conjunction with studies on penetration of drug into central nervous system tumors). Tiazofurin was found to be rapidly eliminated from the plasma and red blood cell fraction of both groups of patients with kinetics consistent with a two-compartment model of elimination. Operative conditions did not significantly change the pharmacokinetics of tiazofurin in CNS patients. Pharmacokinetics were linear over the dose range 500–2700 mg/m2. The data suggest that there is only a small degree of tissue binding of drug and that the drug is not concentrated by tissues. Uptake into RBC was rapid and elimination from RBC was essentially parallel to drug elimination from plasma. There was no evidence that RBC sequestration of drug contributes to toxicity. Much of the drug was excreted unchanged in the urine, but there was little correlation between creatinine clearance and plasma pharmacokinetics of tiazofurin, suggesting that renal tubular secretion may be a more important method of elimination than is glomerular filtration. Patients with high AUC values and low plasma clearance values were particularly prone to develop toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O'Dwyer PJ, Shoemaker DD, Jayaram HN, Johns DG, Cooney DA, Marsoni S, Malspeis L, Plowman J, Davignon JP, Davis RD: Tiazofurin: A new antitumor agent. Invest New Drugs 2:79–84, 1984

    Google Scholar 

  2. Robins RK, Srivastava PC, Narayanan VL, Plowman J, Paull KD: 2-β-D-Ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. J Med Chem 25:107–108, 1982

    Google Scholar 

  3. Earle MF, Glazer RI: Activity and metabolism of 2-β-D-ribofuranosylthiazole-4-carboxamide in human lymphoid tumor cells in culture. Cancer Res 43:133–137, 1983

    Google Scholar 

  4. Jayaram HN, Dion RL, Glazer RI, Johns DG, Robins RK, Srivastava PC, Cooney DA: Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem Pharmacol 31:2371–2380, 1982

    Google Scholar 

  5. Jayaram HN, Smith AL, Glazer RI, Johns DG, Cooney DA: Studies on the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide. (NSC 286193) II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Biochem Pharmacol 31:3839–3845, 1982

    Google Scholar 

  6. Streeter DG, Miller JP: The in vitro inhibition of purine nucleotide biosynthesis by 2-β-D-ribofuranosylthiazole-4-carboxamide. Biochem Biophys Res Commun 103:1409–1415, 1981

    Google Scholar 

  7. Saunders PP, Kuttan R, Lai MM, Robins RK: Action of 2-β-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) in Chinese hamster ovary and variant cell lines. Mol Pharmacol 23:534–539, 1983

    Google Scholar 

  8. Lee HJ, Pawlak K, Nguyen BT, Robins RK, Sadee W: Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin and selenazofurin, studied in mouse lymphoma cell culture. Cancer Res 45:5512–5520, 1985

    Google Scholar 

  9. Fridland A, Connelly MC, Robbins TJ: Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5-nucleotidase. Cancer Res 46:532–537, 1986

    Google Scholar 

  10. Kuttan R, Robins RK, Saunders PP: Inhibition of inosinate dehydrogenase by metabolites of 2-β-D-ribofuranosylthiazole-4-carboxamide. Biochem Biophys Res Commun 107:862–868, 1982

    Google Scholar 

  11. Cooney DA, Jayaram HN, Gebeyehu G, Betts CR, Kelley JA, Marquez VE, Johns DG: The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase inhibitory properties. Biochem Pharmacol 31:2133–2136, 1982

    Google Scholar 

  12. Berger NA, Berger SJ, Catino DM, Petzold SJ, Robins RK: Modulation of nicotinamide adenine dinucleotide and poly (adenosine diphosphoribose) metabolism by the synthetic ‘C’ nucleoside analogs tiazofurin and selenazofurin. J Clin Invest 75:702–709, 1985

    Google Scholar 

  13. Jayaram HN, Cooney DA, Glazer RI, Dion RL, Johns DG: Mechanism of resistance to the oncolytic C-nucleoside (2-β-D-ribofuranosylthiazole-4-carboxamide) (NSC 286193). Biochem Pharmacol 31:2557–2560, 1982

    Google Scholar 

  14. Ahluwalia GS, Jayaram HN, Plowman JP, Cooney DA, Johns DG: Studies on the mechanism of action of 2-β-D-ribofuranosylthiazole-4-carboxamide V. Factors governing the response of murine tumors to tiazofurin. Biochem Pharmacol 33:1195–1203, 1984

    Google Scholar 

  15. Carney DN, Ahluwalia GS, Jayaram HN, Cooney DA, Johns DG: Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells. J Clin Invest 75:175–182, 1985

    Google Scholar 

  16. Lui MS, Faderan MA, Liepnieks JJ, Natsumeda Y, Olah E, Jayaram NH, Weber G: Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide). J Biol Chem 259:5078–5082, 1984

    Google Scholar 

  17. Liepnieks JJ, Faderan MA, Lui MS, Weber G: Tiazofur-ininduced selective depression of NAD content in hepatoma 3924A. Biochem Biophys Res Commun 122:345–349, 1984

    Google Scholar 

  18. Karle JM, Monks A, Wolfe RM, Cysyk RL: Effect of 2-β-D-ribofuranosylthiazole-4-carboxamide on uptake of nucleosides by cultured L1210 cells. Canc Lett 24:11–18, 1984

    Google Scholar 

  19. Chandrasekaran B, Ardalan B: High-performance liquid Chromatographic determination of 2-β-D-ribofuranosylthiazole-4-carboxamide in urine and plasma. J Chromatogr 276:237–242, 1983

    Google Scholar 

  20. Riley CM, Sternson LA, Repta AJ: Analysis of riboxamide in plasma by high-performance liquid chromatography using automated column switching. J Chromatogr 276:93–102, 1983

    Google Scholar 

  21. Ackerly CC, Newman RA, McCormack JJ: A TLC-HPLC method for determination of tiazofurin (NSC 286193) in serum. J Liq Chromatogr 6:1239–1247, 1983

    Google Scholar 

  22. Meltzer NM, Sternson LA: Analysis of riboxamide in urine by high-performance liquid chromatography. J Chromatogr 307:216–219, 1984

    Google Scholar 

  23. Klecker Jr RW, Collins JM: Quantification of tiazofurin in plasma by high-performance liquid chromatography. J Chromatogr 307:361–369, 1984

    Google Scholar 

  24. Obeng EK, Vallner JJ, Gokhale RD: Determination of the antineoplastic agent tiazofurin in plasma by high performance liquid chromatography. Anal Lett 17:607–615, 1984

    Google Scholar 

  25. Melink TJ, Van Hoff DD, Kuhn JG, Hersh MR, Sternson LA, Patton TF, Siegler R, Boldt DH, Clark GM: Phase I evaluation of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Cancer Res 45:2859–2865, 1985

    Google Scholar 

  26. Trump DL, Tutsch KD, Koeller JM, Tormey DC: Phase I clinical study with pharmacokinetic analysis of 2-β-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion. Cancer Res 45:2853–2858, 1985

    Google Scholar 

  27. Batist G, Klecker Jr RW, Jayaram HN, Jenkins JF, Grygiel J, Ihde DC, Eddy JL, Fine RL, Kerr IG, Collins JM: Phase I and pharmacokinetic study of tiazofurin (TCAR, NSC 286193) administered by continuous infusion. Invest New Drugs 3:349–355, 1985

    Google Scholar 

  28. Malspeis L, Neidhart JA, Staubus AE, DeSouza JJV, Dallaire BK, Grillo-Lopez AJ: Tiazofurin pharmacokinetics during a phase I clinical trial. (Abstract) Proc Am Assoc Cancer Res 25:163, 1984

    Google Scholar 

  29. Roberts JD, Ackerly CA, Newman RA, Krakoff IH, Stewart JA: Phase I study of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide; NSC 286193). (Abstract) Proc Am Assoc Cancer Res 25:166, 1984

    Google Scholar 

  30. Kovach JS, McGovern R, Rubin J, Richardson RL, Schutt AJ: Plasma and red blood cell (RBC) pharmacokinetics of tiazofurin (T) and alterations in RBC nucleotides after intravenous T in man. (Abstract) Proc Am Assoc Cancer Res 25:344, 1984

    Google Scholar 

  31. Arnold ST, Jayaram HN, Harper GR, Litterst CL, Malspeis L, DeSouza JV, Staubus AE, Ahluwalia GS, Wilson YA, Cooney DA, Johns DG: The disposition and metabolism of tiazofurin in rodents, rabbits and dogs. Drug Metab Dispos 12:165–173, 1984

    Google Scholar 

  32. Maroun JA, Green R, Stewart DJ: Phase I study of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide). (Abstract) Proc Am Soc Clin Oncol 4:48, 1985

    Google Scholar 

  33. Green RM, Hugenholtz H, Richard M, Dennery J, Hopkins H, Thibault M, Stewart DJ: Human central nervous system pharmacology of tiazofurin. (Abstract) Proceedings of the Second International Symposium on Biology of Brain Tumor, J Neuro-Oncology 2:288, 1984

    Google Scholar 

  34. Powis G: Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol 14:177–183, 1985

    Google Scholar 

  35. Sedman AJ, Wagner JG: CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65:1006–1010, 1976

    Google Scholar 

  36. Loo JCK, Riegelman S: Assessment of pharmacokinetic constants from post infusion blood curves obtained after IV infusion. J Pharm Sci 59:53–55, 1970

    Google Scholar 

  37. Greenblatt DJ, Koch-Weser J: Drug therapy: clinical pharmacokinetics. N Engl J Med 293:702–705, 1975

    Google Scholar 

  38. Sokal RR, Rohlf FJ: Biometry: The principles and practice of statistics in biological research. WH Freeman and Company, San Francisco, 1969, pp 515–517

    Google Scholar 

  39. Jayaram NH, Ahluwalia GS, Arnold S, Harper GR, Cooney DA, Johns DG: The distribution and metabolism of tiazofurin. (Abstract) Proc Am Assoc Cancer Res 24:288, 1983

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Ontario Cancer Treatment and Research Foundation, Ottawa Regional Cancer Center, General Hospital Division, Canada

    Robert M. Green Ph.D., David J. Stewart & Jean A. Maroun

  2. The Department of Medicine, University of Ottawa Faculty of Health Sciences, 501 Smyth Road, K1H 8L6, Ottawa, Ontario, Canada

    David J. Stewart & Jean A. Maroun

Authors
  1. Robert M. Green Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean A. Maroun
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, R.M., Stewart, D.J. & Maroun, J.A. Clinical pharmacology of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Invest New Drugs 4, 387–394 (1986). https://doi.org/10.1007/BF00173513

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173513

Key words

Search

Navigation